Related Experiment Video
Updated: Jun 20, 2026

Robotically Delivered fMRI-Guided Personalized Transcranial Magnetic Stimulation Therapy for Treatment-Resistant Depression
Published on: April 10, 2026
Medical comorbidity affects antidepressant treatment response in patients with melancholic depression
K Pohle1, K Domschke, T Roehrs
1Department of Psychiatry, University of Muenster, Muenster, Germany.
Background:
This study aimed at the impact of medical comorbidity (MC) on response to antidepressant treatment over 6 weeks in diagnostic subtypes of patients with major depressive episode (MDE).
Methods:
In a clinical sample of 241 admitted patients with MDE, MC was assessed by medical specialists and weekly response to antidepressant treatment was assessed with the Hamilton Depression Scale (HAM-D 21).
Results:
Over 6 weeks of treatment, patients with melancholic depression and MC had poorer treatment response on the HAM-D scale and a worse functional outcome (GAF) as opposed to their counterparts without MC, which was first detected after 4 weeks of treatment (p = 0.02). More specifically, subjects with melancholic depression and cardiovascular or endocrinological MC showed significantly poorer treatment response over 6 weeks. Interestingly, these effects were not related to various antidepressant treatment regimens.
Conclusions:
MC has a negative impact on treatment response in patients with melancholic depression.
Related Concept Videos
Antidepressant Drugs: MAOIs and Other Agents
Antidepressant Drugs: Overview
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
Mania and Antimanic Drugs: Overview
Depressive Disorders: MDD and Dysthymia
Drug Therapy
Antianxiety Medications